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1. Experimental procedures and analytical data 
a. General Information 
All reagents purchased from commercial sources were used as received.  Technical solvents 
were bought from VWR international and used as received. 
Flow reactions were performed on a R-series Vapourtec system, using a LED photoreactor 
(450 nm, 24 W, 10 mL coil reactor with FEP tubing). 
UPLC analyses were run on a Waters system (Acquity UPLC® diode array detector (190–400 
nm) controlled by the Empower software) and were performed using an ACQUITY UPLC® 
BEH C18 column (1.7 µm, 2.1 × 100 mm), at 0.5 mL/min and 45°C. Thin layer chromatography 
(TLC) analyses were performed on silica gel Polygram® SIL G/UV254 pre-coated TLC-sheets. 
Semi preparative (Semi-PREP) purifications were performed using SQD Waters single 
quadrupole mass spectrometer. This spectrometer is equipped with an ESI  source, Waters 
2535 quaternary pump coupled with 2767 sample Manager and with diode array detector (210 
to 400 nm.)  The column used is a Waters  Sunfire  ODB MS C18 column (5µm, 30 x 50 mm) 
for acidic purification and a Waters XBridge OBD  MS C18  column (5µm, 30 x 50 mm) for 
basic purification. 
Super Fluid Critical (SFC) purifications were performed using PREP600 system from Pic 
Solution equipped with a diode array detector (220 nm). Columns used are GS-NO2 (10µm, 
50 x 229 mm) and LuxCell4 (20 µm, 50 x 291). 
NMR spectra were recorded on a BRUKER AVANCE III Ultrashield Nanobay 400 MHz NMR 
Spectrometer and on a BRUKER AVANCE III HD Ascend 500 MHz NMR Spectrometer fitted 
with a 5 mm Prodigy BBO 500 S1 cryoprobe. The compounds were analyzed in d6-DMSO 
solution at a probe temperature of 300 K. Chemical shifts are given in ppm downfield from 
TMS (tetramethylsilane) as internal standard. For 19F NMR, chemical shifts are given in ppm 
downfield from TFA (trifluoroacetic acid,  -76.50) as internal standard. The NMR multiplicity 
signals are reported as s = singlet, d = doublet, t = triplet, m = multiplet, br = broad, or 
combinations of thereof. Coupling constants J are quoted in Hz and reported to the nearest 1 
Hz. 
 
HRMS were obtained using a  SYNAPT G2-SI Waters  Q-TOF mass spectrometer. This 
spectrometer is equipped with an ESI  source and a Waters Acquity H-class UPLC with diode 























A solution of KOH (1.68 g, 30.0 mmol, 10 equiv.) and H2O (5 mL) was prepared and placed in 
an ice bath. Then, a solution of 2-mercaptobenzothiazole (32, 0.50 g 3.0 mmol, 1.0 equiv.) in 
THF (5 mL) was added and, after 10 min, the cold bath was removed. The reaction mixture 
was stirred at room temperature for 20 min. Dibromofluoromethane (0.380 mL, 4.8 mmol, 1.6 
equiv.) was then slowly added to the reaction mixture at 0°C. The reaction was stirred at 0oC. 
After 2h, the crude mixture was quenched by addition of H2O (30 mL), and the aqueous phase 
was extracted with DCM (3 x 40 mL). The combined organic layers were dried over anhydrous 
sodium sulfate (Na2SO4), filtered and concentrated under reduced pressure. Purification was 
performed on silica gel chromatography using hexane/ethyl acetate (gradient: starting from 
100% hexane until 10% of ethyl acetate in hexane) to afford compound 1 (0.13 g, 0.47 mmol, 
yield = 16%) as a yellow oil.  
1H NMR (400 MHz, d6-DMSO): δ  8.47 (d, JHF = 56 Hz, 1H), 8.15 (d, JHH =7.6 Hz , 1H), 8.06 
(d, JHH = 7.6 Hz, 1H), 7.58 (t, JHH = 7.6 Hz, 1H), 7.51 (t, JHH = 7.6 Hz, 1H);  
13C NMR (126 MHz, d6-DMSO): δ 199.47, 152.08, 135.76, 126.76, 125.74, 122.43, 122.08, 
90.55 (d, JCF = 295 Hz);  
19F NMR (400 MHz, d6-DMSO + TFA):  δ  -105.51 (d, JHF = 54 Hz, 1F); 





2-(difluoromethylsulfanyl)-1,3-benzothiazole 2 was commercially purchased. 
1H NMR (400 MHz, d6-DMSO): δ  8.16 (d, JHH = 8 Hz, 1H), 8.06 (d, JHH = 8 Hz, 1H), 7.99 (t, 
JHF = 54 Hz, 1H), 7.58 (t, JHH = 7.0 Hz, 1H), 7.52 (t, JHH = 7.0 Hz, 1H);  
13C NMR (126 MHz, d6-DMSO): δ 155.94, 152.28, 135.95, 126.79, 125.83, 122.46, 122.07, 
120.28 (t, JCF = 275 Hz);  
19F NMR (400 MHz, d6-DMSO + TFA):  δ - 94.40 (d, JFH = 54 Hz, 2F); 




























To a round-bottom flask containing 2-((difluoromethyl)thio)benzo[d]thiazole (2, 0.2 g, 1.0 
mmol), were added MeCN (0.5 mL), CCl4 (0.5 mL), H2O (1 mL), NaIO4 (1.07 g, 5.0 mmol) and 
RuCl3·xH2O (3.1 mg, 15 μmol). The resulting reaction mixture was stirred at room temperature 
for 2h. After completion of the reaction, H2O (10 mL) was added, and the aqueous layer was 
extracted with diethyl ether (3 x 15 mL).  
The combined organic layers were washed with saturated aqueous solution of NaHCO3, and 
subsequently dried over anhydrous Na2SO4, filtered and concentrated to dryness. The crude 
was purified by column chromatography (silica gel, n-hexane/ethyl acetate = 90:10) to afford 
compound 3 (0.17 g, 0.67 mmol, 67 % yield) as a colorless solid.  
 
1H NMR (400 MHz, d6-DMSO): δ 8.44 (m, 2H), 7.82 (m, 2H), 7.73 (t, JHF = 52 Hz, 1H) 
13C NMR (126 MHz, d6-DMSO): δ 159.01, 152.41, 137.49, 129.16, 128.55, 125.53, 123.74, 
114.97 (t, JCF = 282 Hz);  
19F NMR (400 MHz, d6-DMSO + TFA): δ -123.97 (d, JFH = 53 Hz, 2F);  








i. General procedures 
 
General procedure A : Flow pseudo PET conditions 
A solution of  2-((Difluoromethyl)sulfonyl)benzo[d]thiazole 3 (30 mg, 0.120 mmol), the 
substrate (1.20 mmol, 10 equiv.) and [Ir(ppy)3] (4 mg, 5 mol%) in DMSO (2.4 mL) was 
prepared. Using the vapourtec flow system (Figure S1), the solution was injected in a 2 
mL loop and pumped with cyclohexane as a solvent at a flow rate of 0.25 mL/min. The 
mixture passed through a flow photochemical reactor (10 mL, 24 W, 450 nm) at 55°C. 
After completion of the residence time, the crude material was collected, and the 
segmented flow of DMSO was filtered and directly injected in a Semi-Prep HPLC/MS 
system for purification. The desired product was finally analyzed by NMR and HRMS. 





Figure S1 : Photochemistry flow instrument used from Vapourtec 
 
General procedure B : Baran Conditions1 
A solution of the substrate (0.40 mmol), Zn(SO2CHF2)2 (250 mg, 0.80 mmol, 2 equiv.) and 
TFA (31 µL, 0.40 mmol, 1 equiv.) in DMSO (1.5 mL) was prepared. Then, tBuOOH (360 µL, 
5.5 M in nonane, 2 mmol, 5 equiv.) was added dropwise, under vigorous stirring at rt for 5h to 
24h. The crude material was purified by Semi-Prep HPLC/MS and the recovered product 
analyzed by NMR and HRMS. 
 
ii. Gradients used for Semi prep purification 
Purification Eluents:  
Solvent A: H2O (100%) 
Solvent B: MeCN  (100%) 
Solvent C: H2O/MeCN (50/50),  TFA + 2%  (pH ~2). 
Solvent D: H2O  + NH4HCO3 100 mM + 500µL/L NH4OH,   (pH ~8.5). 










Gradient 1: Acidic, classic 
Time 
(min) 




0 90 0 10 35 
0.5 90 0 10 35 
9 0 90 10 35 
9.1 0 90 10 45 
12 0 90 10 45 
 
Gradient 2: Acidic, isocratic 95/5 (water/acetonitrile) 
Time 
(min) 




0 90 0 10 35 
0.5 90 0 10 35 
0.6 90 0 10 35 
9 90 0 10 35 
9.1 0 90 10 45 
12 0 90 10 45 
 
Gradient 3: Acidic, gradient 95/5 to 60/40 (water/acetonitrile) 
Time 
(min) 




0 90 0 10 35 
0.5 90 0 10 35 
0.6 90 0 10 35 
9 55 35 10 35 
9.1 0 90 10 45 
12 0 90 10 45 
 
 
Gradient 4: Acidic, gradient 80/20 to 70/30 (water/acetonitrile) 
Time 
(min) 




0 90 0 10 35 
0.5 90 0 10 35 
0.6 75 15 10 35 
9 65 25 10 35 
9.1 0 90 10 45 




12 0 90 10 45 
 
Gradient 5: Acidic, gradient 85/15 to 75/25 (water/acetonitrile) 
Time 
(min) 




0 90 0 10 35 
0.5 90 0 10 35 
0.6 80 10 10 35 
9 70 20 10 35 
9.1 0 90 10 45 
12 0 90 10 45 
 
Gradient 6: Acidic, gradient 55/45 to 35/65 (water/acetonitrile) 
Time 
(min) 




0 90 0 10 35 
0.5 90 0 10 35 
0.6 50 40 10 35 
9 30 60 10 35 
9.1 0 90 10 45 
12 0 90 10 45 
 
Gradient 7: Acidic, gradient 99/1 to 90/10 (water/acetonitrile) 
Time 
(min) 




0 98 0 2 35 
0.5 98 0 2 35 
0.6 98 0 2 35 
9 85 5 10 35 
9.1 0 90 10 45 
12 0 90 10 45 
 
Gradient 8: Basic, classic 
Time 
(min) 
A  (%) B(%) D(%) Flow 
 (mL/min) 
0 90 0 10 35 
0.5 90 0 10 35 
9 0 90 10 35 
9.1 0 90 10 45 




12 0 90 10 45 
 
 
Gradient 9: Basic, gradient 60/40 to 40/60 (water/acetonitrile) 
Time 
(min) 




0 90 0 10 35 
0.5 90 0 10 35 
0.6 55 35 10 35 
9 45 45 10 35 
9.1 0 90 10 45 
12 0 90 10 45 
 
Gradient 11: Basic, gradient 95/5 to 55/45 (water/acetonitrile) 
Time 
(min) 




0 90 0 10 35 
0.5 90 0 10 35 
0.6 90 0 10 35 
9 50 40 10 35 
9.1 0 90 10 45 
12 0 90 10 45 
 
HRMS Eluent:  
Solvent C: H2O/MeCN (95/5) + Formic acid (750µL/L) 
Solvent D: H2O/MeCN (5/95) + Formic acid (500µL/L) 
             pH ~ 3 
 
Time (min) C (%) D (%) Flow 
 (mL/min) 
0 98 2 0.8 
0.3 98 2 0.8 
3 5 95 0.8 
4 5 95 0.8 
4.1 98 2 0.8 












2-amino-8-(difluoromethyl)-7-(2-hydroxyethoxymethyl)-9H-purin-6-ol / CHF2-Acyclovir 
(5) 
5   
The general procedure A using acyclovir (0.120 mmol) yielded after purification (acidic mode, 
gradient 2) to 5.0 mg (15%) of the title compound as a colorless solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 10,82 (s, 1H), 7.14 (t, JHF = 52 Hz, 1H), 6,72 (s broad, NH2, 
2H), 5,46 (s, 2H), 3,40 (m, 4H); 
13C NMR (126 MHz, d6-DMSO): δ 156.0, 154.1, 152.2, 138.44 (t, JCF = 27 Hz), 115.53, 109.45 
(t, JCF = 236 Hz), 71.67, 70.62, 59.79; 
19F NMR (500 MHz, d6-DMSO + TFA): δ - 118.14 (d, JFH = 52 Hz, 2F); 
HRMS (m/z): [M+H]+ calcd. for C9H12N5O3F2, 276.0920; found, 276.0914. 
 
4-(difluoromethyl)-1H-indole (6) 
6   
The general procedure B using indole (1 mmol) yielded after purification (basic mode, gradient 
9) to 1.5 mg (1%) of the title compound as a purple oil. 
 
1H NMR (400 MHz, d6-DMSO): δ 11.4 (s, 1H, NH), 7.58 (d, JHH = 7.4 Hz, 1H), 7.48 (t, JHH = 
2.7 Hz, 1H), 7.24 (t, JHF = 56 Hz, 1H), 7.22-7.05 (m, 2H), 6.60 (s broad, 1H); 
13C NMR (126 MHz, d6-DMSO): δ 142.7, 134.7, 131.66, 123.76, 121.25 (t, JCF = 6 Hz), 121.10, 
120.91, 117.45, 113.54 (t, JCF = 236 Hz); 
19F NMR, (400 MHz, d6-DMSO + TFA):  δ -111.48 (d, JFH= 55 Hz, 2F); 
HRMS (m/z): [M+H]+ calcd. for C9H8NF2, 168.0625; found, 168.0632. 
 
2-(difluoromethyl)-1H-benzimidazole (7a), 4-(difluoromethyl)-1H-benzimidazole (7b) 
and  5-(difluoromethyl)-1H-benzimidazole (7c) 




7a 7b 7c     
The general procedure A using benzimidazole (0.15 mmol) yielded after purification (acidic 
mode, gradient 2) to 1.5 mg of 7a (6%), 0.9 mg of 7b (2.5 %) and 0.5 mg of 7c (1.5%) as 
colorless solids. 
 
7a   
1H NMR (400 MHz, d6-DMSO): δ 7.66 (dd, JHH = 3.2 Hz, 2H), 7.31 (dd, JHH =3.2 Hz, 2H), 7.27 
(t, JHF = 53 Hz, 1H); 
13C NMR (126 MHz, d6-DMSO): δ 145.49 (t, JCF = 28 Hz), 123.24, 116.1, 109.9 (t, JCF = 236 
Hz); 
19F NMR (500 MHz, d6-DMSO + TFA): δ -117.08 (d, JFH = 53 Hz , 2F); 
HRMS (m/z): [M+H]+ calcd. for C8H7N2F2, 169.0577; found, 169.0582. 
 
7b  
1H NMR (400 MHz, d6-DMSO): δ 9.01 (s, 1H), 7.92 (d, JHH = 8.1 Hz, 1H), 7.62 (d, JHH = 8.1 
Hz, 1H), 7.51 (d, JHH = 7.8 Hz, 1H), 7.44 (t, JHF = 55 Hz, 1H); 
13C NMR (126 MHz, d6-DMSO): δ 136.30, 126.69, 124.67 (t, JCF = 22 Hz), 124.07 (t, JCF = 3 
Hz), 116.98 (t, JCF = 7.5 Hz), 116.02 (t, JCF = 236 Hz), 114.27, 99.4; 
19F NMR (500 MHz, d6-DMSO + TFA): δ -112.86 (d, J = 55 Hz, 2F); 




1H NMR (400 MHz, d6-DMSO): δ 8.80 (s, 1H), 7.91 (s, 1 H), 7.81 (d, JHH = 8.1 Hz, 1H), 7.53 
(d, JHH = 8.6 Hz, 1H), 7.16 (t, JHF = 55 Hz, 1H); 
13C NMR (126 MHz, d6-DMSO) δ 157.97, 157.71, 143.32, 139.72, 129.14 (t, JCF = 3 Hz), 
120.53, 115.46, 115.32 (t, JCF = 236 Hz); 
19F NMR (500 MHz, d6-DMSO + TFA): δ -108.94 (d, JFH = 56 Hz, 2F); 








2-(difluoromethyl)-4-methyl-1H-pyrrolo[2,3-b]pyridine (8a) and  6-(difluoromethyl)-4-
methyl-1H-pyrrolo[2,3-b]pyridine (8b) 
8a 8b   
The general procedure B using 4-methyl-1H-pyrrolo[2,3-b]pyridine (0.40 mmol) yielded after 




1H NMR (400 MHz, d6-DMSO): δ 8.25 (d, JHH = 5 Hz, 1H), 7.23 (t, JHF = 54 Hz, 1H), 7.04 (d, 
JHH = 5 Hz, 1H), 6.93 (t, JHH = 2 Hz, 1H), 2.57 (s, 3H); 
13C NMR (126 MHz, d6-DMSO): δ 146.80, 143.38, 142.58, 130.72 (t, JCF = 25 Hz), 119.82, 
116.92, 110.73 (t, JCF = 234 Hz), 100.14 (t, JCF = 7 Hz), 18.13; 
19F NMR (500 MHz, d6-DMSO + TFA): δ -111.95 (d, JFH = 55 Hz, 2F); 
HRMS (m/z): [M+H]+ calcd. for C9H9N2F2, 183.0734; found, 183.0735. 
8b  
1H NMR (400 MHz, d6-DMSO): δ 11.9 (s broad, 1H), 7.6 (t, JHH = 3 Hz, 1H), 7.2 (s, 1H), 6.91 
(t, JHF = 55 Hz, 1H), 6.59 (m, 1H), 2.58 (s, 3H); 
13C NMR (126 MHz, d6-DMSO): δ 147.18, 144.88 (t, JCF = 24 Hz), 139.96, 127.45, 121.48, 
114.97 (t, JCF = 240 Hz), 112.15, 98.76, 18.16; 
19F NMR (500 MHz, d6-DMSO + TFA): δ -113.25 (d, JFH = 55 Hz, 2F); 
HRMS (m/z): [M+H]+ calcd. for C9H9N2F2, 183.0734; found, 183.0735. 
 
4-(difluoromethyl)-6-methyl-1H-pyrazolo[3,4-b]pyridine (9a) and  3-(difluoromethyl)-6-
methyl-1H-pyrazolo[3,4-b]pyridine (9b) 
9a 9b    
The general procedure A using 6-methyl-1H-pyrazolo[3,4-b]pyridine (0.30 mmol) yielded after 
purification (acidic mode, gradient 3) to 2.1 mg (4%) of 9a as a colorless solid and 1.3mg of 
9b (3%) as a yellowish solid. 
 





1H NMR (400 MHz, d6-DMSO):  δ  7.5 (s, 1H), 7.38 (t, JHF = 55 Hz, 1H), 7.27 (s,1H), 2.65 (s, 
3H); 
13C NMR (126 MHz, d6-DMSO): δ 158.53, 152.33, 135.03 (t, JCF = 24 Hz), 131.38, ), 113.94 
(t, JCF = 7 Hz), 113.88 (t, JCF = 237 Hz), 111.84, 24.41; 
19F NMR (500 MHz, d6-DMSO + TFA): δ -112.62 (d, JFH = 56 Hz, 2F); 
HRMS (m/z): [M+H]+ calcd. for C8H8N3F2, 184.0686; found, 184.0688. 
 
9b  
1H NMR (400 MHz, d6-DMSO): δ 8.17 (d, JHH = 8 Hz, 1H), 7.3 (t, JHF = 54 Hz, 1H), 7.21 (d, JHH 
= 8 Hz, 1H), 2.62 (s, 3H); 
13C NMR (126 MHz, d6-DMSO): δ 159.26, 152.13, 137.65 (t, JCF = 29 Hz), 129.08, 118.63, 
114.29, 112.45 (t, JCF = 230 Hz), 108.83, 24.47; 
19F NMR (400 MHz, d6-DMSO + TFA): δ  -115.48 (d, JFH = 55 Hz, 2F); 





The general procedure B using 2-(3,5-dichloro-4-pyridyl)-N,N-dimethyl-acetamide (0.25 
mmol) yielded after purification (acidic mode, gradient 1) to 7.4  mg (10%) of the title compound 
as a colorless solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 8.75 (s, 1H), 7.23 (t, JHF = 56Hz, 1H), 4.11 (s, 2H), 3.15 (s, 
3H), 2,86 (s, 3H); 
13C NMR (126 MHz, d6-DMSO): δ 166.02, 146.49, 146.14 (t, JCF = 23 Hz), 144.61, 135.01, 
131.49, 112.00 (t, JCF = 240 Hz), 36.89, 35.58, 35.01; 
19F NMR (500 MHz, d6-DMSO + TFA): δ -119.44 (d, JFH = 53 Hz, 2F); 
HRMS (m/z): [M+H]+ calcd. for C10H11N2OF2Cl2, 283.0216; found, 283.0216. 
 
3-chloro-1-(difluoromethyl)-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carbonitrile (11) 





The general procedure B using 3-chloro-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carbonitrile 
(0.40 mmol) yielded after purification (acidic mode, gradient 6) to 6.0 mg (7 %) of the title 
compound as a colorless solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 7.07 (t, JHF = 52 Hz, 1H), 3.13 (m, 4H), 2.2 (q, JHH = 8 Hz, 
2H); 
13C NMR (126 MHz, d6-DMSO): δ 165.94, 148.72 (t, JCF = 26 Hz), 147.96, 138.75, 114.6, 
112.71 (t, JCF = 240 Hz), 108.30, 32.46, 29.17, 24.3; 
19F NMR (500 MHz, d6-DMSO + TFA): -120.72 (d, JFH = 53 Hz, 2F); 




The general procedure B using 2-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile 
(0.40 mmol) yielded after purification (acidic mode, gradient 6) to 7.5 mg (8%) of the title 
compound as a brown solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 7.29 (t, JHF = 52 Hz, 1H), 3.08 (m, 4H), 2.12 (q, JHH = 8 Hz, 
2H); 
13C NMR (126 MHz, d6-DMSO): δ 173.46, 151.38, 141.10 (t, JCF = 24 Hz), 135.33 (t, JCF = 4 
Hz), 113.75, 111.84 (t, JCF = 240 Hz), 103.41 (t, JCF = 4 Hz), 33.88, 28.54, 22.20; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -117.27 (dt, JFH = 54 Hz, JFH’ = 2Hz, 2F); 




The general procedure B using 2-tetrahydropyran-4-ylpyrimidin-5-amine (0.40 mmol) yielded 
after purification (acidic mode, gradient 5) to 7.4 mg (7 %) of the title compound as a colorless 
solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 8.35 (s, 1H), 6.93 (t, JHF = 52 Hz, 1H), 3.90 (d, JHH = 12 Hz, 
2H), 3.42 (t, JHH = 12 Hz, 2H), 2.91 (m, 1H), 1.74 (m, 4H); 




13C NMR (126 MHz, d6-DMSO): δ 159.27, 146.89, 138.21 (t, JCF = 23 Hz), 137.84, 113.49 (t, 
JCF = 236 Hz), 66.80, 42.02, 31.32; 
19F NMR (500 MHz, d6-DMSO + TFA): δ -112.21 (d, JFH = 54 Hz, 2F); 





The general procedure B using 4-chloro-6-methoxy-pyrimidin-5-amine (0.40 mmol) yielded 




1H NMR (400 MHz, d6-DMSO): δ 6.69 (t, JHF = 54 Hz, 1H), 5.95 (s, 2H), 4.01 (s, 3H); 
13C NMR (126 MHz, d6-DMSO) δ 157.39, 143.91 (t, JCF = 26 Hz), 136.54, 128.96, 11.90 (t, JCF 
= 245 Hz), 54.76; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -118.75 (d, JFH = 52 Hz, 2F); 





The general procedure A using 5-methylpyrimidin-2-amine (0.15 mmol) yielded after 
purification (basic mode, gradient 10) to 6.3 mg (26%) of the title compound as a colorless 
solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 8.25 (s, 1H), 6.77 (t, JHF = 52 Hz, 1H), 6.75 (s broad, 2H), 
2.15 (s, 3H); 13C NMR (126 MHz, d6-DMSO) δ 162.10, 161.49, 156.74 (t, JCF = 23 Hz), 115.15, 
113.74 (t, JCF = 240 Hz), 12.61; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -130.32 (d, JFH = 53 Hz, 2F); 








The general procedure B using 2-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one (0.40 
mmol) yielded after purification (acidic mode, gradient 5) to 10.8 mg (13 %) of the title 
compound as a colorless solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 11.07 (s, 1H), 6.99 (t, JHF = 52 Hz, 1H), 3.01 (t, JHH = 8 Hz, 
2H), 2.59 (t, JHH = 8 Hz, 2H); 
13C NMR (126 MHz, d6-DMSO): δ 170.92, 165.43, 159.58, 154.19 (t, JCF = 24 Hz), 113.22 (t, 
JCF = 236 Hz), 111.25, 29.28, 24.94, 18.07; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -119.75 (d, JFH = 54 Hz, 2F); 





The general procedure B using 2-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one (0.40 
mmol) yielded after purification (acidic mode, gradient 2) to 14  mg (20%) of the title compound 
as a yellowish solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 12.1 (s, 1H), 11.2 (s broad, 1H), 9.42 (s, 1H), 7.54 (t, JHF = 
53 Hz, 1H); 
13C NMR (126 MHz, d6-DMSO): δ 160.72, 150.22, 148.24, 143.17 (t, JCF = 23 Hz), 137.20, 
111.86, 110.43 (t, JCF = 238 Hz); 
19F NMR (500 MHz, d6-DMSO + TFA): δ -122.68 (d, JFH = 53 Hz, 2F); 





The general procedure A using methyl 2-(3,5-dichloro-1-tetrahydropyran-2-yl-pyrazolo[3,4-
b]pyridin-4-yl)acetate (0.48 mmol, 8 equiv.) yielded after purification (basic mode, gradient 8) 
to 5.0 mg (3 %) of the title compound as a colorless solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 7.37 (t, JHF = 53 Hz, 1H), 6.04 (dd, JHH = 10 Hz, J’HH = 2 Hz, 
1H), 4.4 (s, 2H), 3.95 (d, JHH = 10 Hz, 1H), 3.73 (m, 1H),  3.69 (s, 3H), 2.37 (m, 1H), 2.0 (m, 
2H), 1.8 (m, 1H), 1.58 (m, 2H); 
13C NMR (126 MHz, d6-DMSO): δ 168.47, 148.15 (t, JCF = 23 Hz), 147.20, 138.46, 131.37, 
124.02, 113.93,  111.92 (t, JCF = 240 Hz), 81.90, 67.22, 52.61, 33.62, 28.58, 24.50, 21.99; 




19F NMR (400 MHz, d6-DMSO + TFA): δ -120.84 (dd, JFH = 53 Hz, JFH = 29 Hz, 2F); 





The general procedure B using 6-methyl-2-methylsulfanyl-8H-pyrimido[4,5-d]pyrimidine-5,7-
dione (0.40 mmol) yielded after purification (acidic mode, gradient 1) to 8.5  mg (7.7%) of the 
title compound as a yellow solid. 
 
 1H NMR (400 MHz, d6-DMSO): δ 12.57 (s, 1H), 7.68 (t, JHF = 53 Hz, 1H), 3.21 (s, 3H), 2.60 
(s, 3H); 
13C NMR (126 MHz, d6-DMSO) δ 175.99, 160.17, 159.23 (t, JCF = 22 Hz), 157.02, 150.06, 
108.93 (t, JCF = 241 Hz), 101.61 (t, JCF = 3 Hz), 27.18, 13.77; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -125.60 (d, JFH = 53 Hz, 2F); 
HRMS (m/z): [M+H]+ calcd. for C9H9N402F2S , 275.0414; found, 275.0417. 
 
8-(difluoromethyl)-1,3,7-trimethyl-purine-2,6-dione / CHF2-caffeine (20) 
20  
The general procedure A using caffeine (0.30 mmol, 5 equiv.) in DMF yielded after purification 
(acidic mode, gradient 2) to 2.5 mg (4%) of the title compound as a colorless solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 7.35 (t, JHF = 52 Hz, 1H), 4.03 (s, 3H),3.42 (s, 3H), 3.24 (s, 
3H); 
13C NMR (126 MHz, d6-DMSO): δ 154.85, 150.85, 146.55, 142.6 (t, JCF = 27 Hz), 108.52, 
108.47 (t, JCF = 236 Hz), 32.42, 29.48, 27.69; 
19F NMR (500 MHz, d6-DMSO + TFA): δ -119.98 (d, JFH = 52 Hz, 2F); 
HRMS (m/z): [M+H]+ calcd. for C9H11N4O2F2, 245.0850; found, 245.0854. 
Data in accordance with litterature[1,2] 
 
8-(difluoromethyl)-1,3-dimethyl-7H-purine-2,6-dione / CHF2-theophylline (21) 
21  
The general procedure A, using theophylline (0.30 mmol, 5 equiv.) in DMF yielded after 
purification (acidic mode, gradient 4) to 2.5 mg (5%) of the title compound as a colorless solid. 





1H NMR (400 MHz, d6-DMSO): δ 7.13 (t, JHF = 56 Hz, 1H), 3.43 (s, 3H), 3.24 (s, 3H); 
13C NMR (126 MHz, d6-DMSO): δ 154.58, 151.07, 147.14, 143.22 (t, JCF = 26 Hz), 108.66 (t, 
JCF = 236 Hz), 108.17, 29.85, 27.87; 
19F NMR (500 MHz, d6-DMSO + TFA): δ -118.57 (d, JFH = 52 Hz, 2F); 
HRMS (m/z): [M+H]+ calcd. for C8H9N4O2F2, 231.0694; found, 231.0697. 
 
Data in accordance with litterature[1] 
 
 





The general procedure B using pentoxyfilline (0.40 mmol) yielded after purification (acidic 
mode, gradient 1) to 9  mg (6.8%) of the title compound as a colorless solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 7.35 (t, JHF = 52 Hz, 1H), 4.03 (s, 3H), 3.85 (t, JHH = 7 Hz, 
2H), 3.42 (s, 3H), 2.46 (t, JHH = 7 Hz, 2H), 2.07 (s, 3H), 1.56-1.40 (m, 4H); 
13C NMR (126 MHz, d6-DMSO): δ 208.20, 154.64, 150.55, 146.60, 142.70 (t, JCF = 27 Hz), 
108.48, 108.47 (t, JCF = 235Hz), 42.19, 40.33, 32.41, 29.73, 29.43, 26.88, 20.49; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -119.37 (d, JFH = 52 Hz, 2F); 
HRMS (m/z): [M+H]+ calcd. for C14H19N4O3F2, 329.1425; found, 329.1423. 
 
Data in accordance with litterature[1],[2] 
 
5-(difluoromethyl)-1,3-dimethyl-pyrimidine-2,4-dione/ CHF2-1,3-dimethyl-uracil (23) 
23  
The general procedure A using dimethyl-uracil (0.40 mmol) yielded after purification (acidic 
mode, gradient 2) to 6.0 mg (26%) of the title compound as a colorless solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 8.17 (s, 1H), 6.75 (t, JHF = 56 Hz, 1H), 3.36 (s, 3H), 3.17 (s, 
3H); 
13C NMR (126 MHz, d6-DMSO): δ 160.41, 150.91, 144.71, 112.02 (t, JCF = 235 Hz), 105.01 (t, 
JCF = 23 Hz), 36.81, 27.30; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -117.78 (d, JFH = 55 Hz, 2F); 
HRMS (m/z): [M+H]+ calcd. for C7H9N2O2F2, 191.0632; found, 191.0634. 
 
Data in accordance with litterature[2] 






pyrimidin-2-one / CHF2-Cytosine (24) 
24a 24b  
The general procedure B using cytosine (0.40 mmol) yielded after purification (SFC mode, 




1H NMR (500 MHz, d6-DMSO):  δ  7.98 (s, 1H), 6.85 (t, JHF = 54 Hz, 1H); 
13C NMR (126 MHz, d6-DMSO) δ 160.3, 152.1, 146.5, 113.1 (t, JCF = 235 Hz), 98.9; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -115;89 (d, JFH = 53 Hz, 2F); 
HRMS (m/z): [M+H]+ calcd. for C5H6N3OF2, 162.0479 ; found, 162.0481. 
 
NB : As less than 1 mg of product was obtained, carbons assignments were determined by 
HSQC and HMBC analysis. 
2 peaks at 9.48 and 8.48 ppm in the proton spectrum are observed, corresponding to the 
degradation of the difluoromethylated compound into the corresponding aldehyde. 
24b  
1H NMR (400 MHz, d6-DMSO): δ 9.75 (s, 1H), 8.79 (s, 1H), 6.87 (t, JHF = 54 Hz, 1H), 6.24 (s, 
1H); 
13C NMR (126 MHz, d6-DMSO) δ 160.52, 149.29 (t, JCF = 25 Hz), 148.69, 109.23 (t, JCF = 241 
Hz), 91.61 (t, JCF = 8 Hz); 
19F NMR (400 MHz, d6-DMSO + TFA): δ -125.02 (d, JFH = 53 Hz, 2F); 
HRMS (m/z): [M+H]+ calcd. for C5H6N3OF2, 162.0479; found, 162.0485. 
 
8-(difluoromethyl)-9H-purin-6-amine / CHF2-Adenine (25) 
25  
The general procedure B using adenine (0.40 mmol) yielded after purification (acidic mode, 
gradient 7) to 4.5 mg (6%) of the title compound as a colorless solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 8.50 (s, 1H), 7.31 (t, JHF = 53 Hz, 1H); 




13C NMR (126 MHz, d6-DMSO) δ 152.03, 150.05, 147.25, 145.46 (t, JCF = 27 Hz), 117.52, 
109.16 (t, JCF = 234 Hz); 
19F NMR (400 MHz, d6-DMSO + TFA): δ -118.33 (d, JFH = 53 Hz, 2F); 
HRMS (m/z): [M+H]+ calcd. for C6H5F2N5, 186.0591; found, 186.0593. 
 
 (1S)-5-(difluoromethyl)-1-[(3R,4S,5R)-3,4-dihydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione / CHF2-uridine (26) 
 
26  
The general procedure B using uridine (0.40 mmol) yielded, after purification (acidic mode, 
gradient 7) to 2.5 mg (2.1%) of the title compound as a colorless oil. 
 
1H NMR (400 MHz, d6-DMSO): δ 8.48 (s, 1H), 6.68 (t, JHF = 54 Hz, 1H), 5.77 (d, JHH = 4.5 Hz, 
1H), 4.04 (t, JHH = 5 Hz, 1H), 3.98 (t, JHH = 5 Hz, 1H), 3.92-3.88 (m, 1H); 
13C NMR (126 MHz, d6-DMSO) δ 160.98 (t, JCF = 3 Hz), 150.25, 141.10 (t, JCF = 7.5 Hz), 
112.10 (t, JCF = 234 Hz), 107.53 (t, JCF = 23 Hz), 88.83, 84.97, 74.33, 69.58, 60.36; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -117.91 (dd, JFH = 40 Hz, JFH’ = 54 Hz, 2F); 
HRMS (m/z): [M-H]- calcd. for C10H11N2O6F2, 293.0585; found, 293.0590. 
 
(1S)-4-amino-5-(difluoromethyl)-1-[(3R,4S,5R)-3,4-dihydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one / CHF2-cytidine (27) 
 
27  
The general procedure B using cytidine (0.40 mmol) yielded after purification (SFC mode, 
isocratic 75/25 CO2/EtOH)  to 0.5 mg (1%) of the title compound as a colorless oil. 
 
1H NMR (500 MHz, d6-DMSO):  δ  8.5 (s, 1H), 6.81 (t, JHF = 54 Hz), 5.74 (s, 1H), 3.99-3.93 
(m, 2H), 3.91-3.86 (m, 1H), 3.72 (d, JHH = 13 Hz, 1H), 3.57 (d, JHH = 13Hz, 1H); 
13C NMR (126 MHz, d6-DMSO): δ 160.3, 152.9, 142.9, 112.5 (t, JCF = 222 Hz), 89.3, 83.7, 
74.0, 68.3, 59.5; 
19F NMR (400 MHz, d6-DMSO + TFA):  δ -115.44  (dd, JHF = 54 Hz, JHF = 15 Hz, 2F); 
HRMS (m/z): [M+H]+ calcd. for C10H14N3O5F2, 294.0802; found, 294.0897. 
 
NB : The compound degrades easily, caution should be taken during the purification and the 
following evaporation.  




As less than 1 mg of product was obtained, carbons assignments were determined by 
HSQC and HMBC analysis. 
 
(3R,4S,5R)-2-[(9S)-6-amino-8-(difluoromethyl)purin-9-yl]-5-(hydroxymethyl) 
tetrahydrofuran-3,4-diol /CHF2-Adenosine (28) 
28   
The general procedure B using adenosine (0.40 mmol) yielded after purification (acidic mode, 
gradient 7) to 4.2  mg (3.3%) of the title compound as a colorless solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 8.22 (s, 1H), 8.20 (s, 2H), 7.41 (t, JHF = 52 Hz, 1H), 5.97 (d, 
JHH = 7 Hz, 1H), 4.87 (dd, JHH = 5 Hz, JHH’ = 7 Hz, 1H), 4.20 (dd, JHH = 2 Hz, JHH’ = 5 Hz, 1H), 
4.03 (m, 1H), 3.60 (m, 2H); 
13C NMR (126 MHz, d6-DMSO) δ 164.16, 157.19, 154.25, 150.28, 118.57, 109.68 (t, JCF = 237 
Hz), 89.11, 97.13, 72.71, 71.05, 62.23; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -115.1 (dd, JFH = 53Hz, JFF’ = 319 Hz, 1F), -118.6 
(dd, JFH = 53Hz, JFF’ = 319 Hz, 1F); 
HRMS (m/z): [M+H]+ calcd. for C11H14N5O4F2, 318.1014; found, 318.1017. 
 
(9S)-2-amino-8-(difluoromethyl)-9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) 
tetrahydrofuran-2-yl]-1H-purin-6-one / CHF2-Guanosine (29) 
29   
The general procedure B using guanosine (0.40 mmol) yielded after purification (acidic mode, 
gradient 7) to 5.2 mg (4%) of the title compound as a colorless solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 7.26 (t, JHF = 52 Hz, 1H), 6.62 (s, 2H), 5.82 (d, JHH = 6 Hz, 
1H), 5.40 (d, JHH = 6 Hz), 5.1-5.04 (m, 2H), 4.73-4.66 (m, 1H), 4.14 (s, 1H), 3.90 (q, JHH = 4 
Hz), 3.70-3.62 (m, 1H), 3.61-3.51 (m, 1H); 
13C NMR (126 MHz, d6-DMSO) δ 157.02, 154.39, 152.29, 138.43 (t, JCF = 26 Hz), 116.49, 
109.51 (t, JCF = 236 Hz), 88.04, 85.98, 72.06, 70.38, 61.71; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -110.55 (dd, JFH = 54 Hz, JFF’ = 316 Hz, 1F), -115.32 
(dd, JFH = 54 Hz, JFF’ = 316 Hz, 1F); 
HRMS (m/z): [M+H]+ calcd. for C11H14N5O5F2 , 334.0963; found, 334.0964. 
 









The general procedure B using 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-
pyrimidin-5-amine (0.40 mmol) yielded after purification (acidic mode, gradient 4) to 7.2 mg 
(7.9 %) of the title compound as a colorless solid. 
 
1H NMR (400 MHz, d6-DMSO): δ 6.76 (t, JHF = 54 Hz, 1H), 6.48 (s, 2H), 3.92 (s, 3H), 3.35 (s, 
4H); 
13C NMR (126 MHz, d6-DMSO): δ 163.80, 158.07, 149.58, 148.55 (t, JCF = 25 Hz), 132.12, 
111.87 (t, JCF = 240 Hz), 54.52, 41.77; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -119.40 (d, JFH = 53 Hz, 2F); 















The general procedure A using (4R)-1-(4-pyridylmethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-
one (39) (0.30 mmol) yielded after purification (acidic mode, gradient 1, then basic mode, 
gradient 8) to 5 mg (16%) of 31a,  400 µg (1.5%) of 31b and 250 µg of 31c (1%) as colorless 
solids. 
 







1H NMR (400 MHz, d6-DMSO): δ 8.65 (d, JHH = 5 Hz, 1H), 7.55  (s, 1H), 7.46 (d, JHH = 4.6 Hz, 
1H), 7.33 (dd, JHH = 6.8 Hz, J’HH = 8.5 Hz, 2H), 6.95 (t, JHF = 54 Hz, 1H), 4.61 (d, JHH = 15 Hz, 
1H), 4.49 (d, JHH = 15 Hz, 1H), 3.69 (m, 2H), 3.29 (m, 1H), 2.76 (dd, JHH = 7 Hz, J’HH = 15 Hz, 
1H), 2.60 (dd, JHH = 7 Hz, J’HH = 15Hz, 1H); 
13C NMR (126 MHz, d6-DMSO) δ 173.52, 152.68 (t, JCF = 24 Hz), 150.61 (ddd, JCF = 4 Hz, J’CF 
= 10 Hz, J’’CF = 248 Hz), 150.37, 148.55, 140.01 (m), 137.98 (td, JCF = 16 Hz, J’CF = 248 Hz), 
124.96, 119.51 (t, JCF = 4 Hz), 114.19 (t, JCF = 238 Hz), 112.41 (dd, JCF = 4 Hz, J’CF = 17 Hz), 
53.50, 44.99, 37.73, 36.87; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -116.92 (d, JFH = 53 Hz, 2F), -136.72 (dd, JFH = 8 Hz, 
J’FF = 22 Hz, 2H), -165.69 (tt, JFH = 8 Hz , J’FF = 22 Hz, 1H); 






1H NMR (400 MHz, d6-DMSO): δ 8.77 (s, 1H), 7.38 (m, 2H), 7.31 (t, JHF = 54 Hz, 1H), 4.72 (d, 
JHH = 15Hz, 1H), 4.52 (d, JHH = 15Hz, 1H), 3.68 (m, 2H), 2.75 (dd, JHH = 8 Hz, J’HH = 15 Hz, 
1H), 2.31 (dd, JHH = 8 Hz, J’HH = 15 Hz, 1H); 
13C NMR (126 MHz, d6-DMSO) δ 173.7, 152.9, 147.6, 145.0, 136.9, 127.5, 123.0, 114.3, 
112.6, 53.4, 42.0, 37.8, 36.9; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -115.66 (d, JFH = 55 Hz, 2F), -138.37 (dd, JFH = 9 Hz, 
J’FF = 21 Hz, 2H), -167.29 (tt, JFH = 7 Hz , J’FF = 22 Hz, 1H); 









1H NMR (400 MHz, d6-DMSO): δ 8.54 (d, JHH = 5 Hz, 2H), 8.53 (s, 1H), 7.62 (m, 1H), 7.42 (t, 
JHF = 52 Hz, 1H), 7.28 (d, JHH = 5 Hz, 2H), 4.52 (d, JHH = 14 Hz, 1H), 4.41 (d, JHH = 14 Hz, 1H), 
4.09 (t, JHH = 8 Hz, 1H), 3.62 (t, JHH = 8 Hz, 1H), 2.75 (dd, JHH = 8.5 Hz, J’HH = 16 Hz, 1H), 2.60 
(d, JHH = 9 Hz, 1H); 
13C NMR (126 MHz, d6-DMSO) δ 172.2, 149.4, 145.9, 145.7, 122.2, 117.1, 111.8, 94.9, 53.1, 
44.4, 31.9; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -113.73 (dd, JFH = 52 Hz, JFF = 11Hz, 2F), -132.53 
(q, JFF = 11 Hz, 1H), -141.10 (m, 1H), -164.52 (td, JFH = 7 Hz, JFF = 22 Hz, 1H); 
HRMS (m/z): [M+H]+ calcd. for C17H14N2OF5, 357.1026; found, 357.1026. 
 
NB : As less than 1 mg of product was obtained for compounds 31b and 31c, carbons 
assignments were determined by HSQC and HMBC analysis. 
 
 
d. Synthesis of the different precursors 
i. Synthesis of moxonidine analogue (36) 
 
36 was synthetized using a 2 steps approach procedure, previously reported  by B. A. Czeskis 








To a suspension of 4,6-dichloropyrimidin-5-amine 33 (1 g, 5.9 mmol) in POCl3 (10mL) was 
added 1-acetylimidazolidin-2-one 34 (781 mg, 5.9 mmol, 1 equiv.). The reaction was stirred 
at 105°C. After 3h, the crude mixture was cooled down to room temperature, and POCl3 was 
evaporated under reduced pressure. The residue was treated with ice water, and aqueous 
NaOH was added until obtention of a pH>10. Then, the mixture was extracted twice with DCM. 
The combined organic layers, were then washed with brine, dried over anhydrous sodium 
sulfate (Na2SO4) and concentrated under reduced pressure. Purification on silica gel 
chromatography (isocratic: 50/50 heptane/ethyl acetate) provided compound 35 (0.60 g, 2.2 
mmol, yield = 38%) as a colorless solid.  
1H NMR (400 MHz, d6-DMSO): δ 8.50 (s, 1H), 7.54 (s, 1H), 3.90 (t, JHH = 7 Hz, 2H), 3.38 (t, 
JHH = 3 Hz, 3H); 
13C NMR (126 MHz, d6-DMSO): δ 169.48, 153.37, 150.38, 150.14, 139.56, 43.77, 38.00, 
24.71; 











Sodium methoxide in MeOH (0.5 N, 3 mL, 1.55 mmol, 1.1 equiv.) was added to 35 (450 mg, 
1.3 mmol) The reaction was refluxed at 65°C. After 3h, the crude mixture was cooled down, 
the formed precipitate was filtered and washed twice with H2O to afford compound 36 (0.275 
g, 1.2 mmol, yield = 92%) as a colorless solid.  
 
1H NMR (400 MHz, d6-DMSO): δ 8.13 (s, 1H), 6.29 (s, 1H), 3.88 (s, 3H), 3.34 (s, 4H); 
13C NMR (126 MHz, d6-DMSO): δ 163.50, 157.94, 150.22, 147.80, 130.49, 54.10, 41.79; 




ii. Synthesis of SV2A-PET (39) 
 
(4R)-1-(4-pyridylmethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one (39) 
39 was synthetized in one step starting from 37 and 38 (the synthesis of an analogue of 38 is 





To a solution of (4R)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one 38 (1 g, 4.64 mmol) and 4-
(bromomethyl)pyridine 37 (0.8 g, 4.64 mmol, 1 equiv.) in THF (5 mL) was added NaH (371 
mg, 9.3 mmol, 2 equiv., 60% in oil) portionwise. The reaction was stirred at 50°C. After 1h, the 
crude mixture was filtered over celite and evaporated under reduced pressure. The residue 
was taken in DCM (20mL), H2O was added (20 mL), and the aqueous phase was extracted 
with DCM (3 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate 
(Na2SO4), filtered and concentrated under reduced pressure. Purification on silica gel 
chromatography (gradient: starting from 100% DCM until 90/10 DCM/MeOH) to afford 
compound 39 (0.80 g, 2.6 mmol, yield = 56%) as a yellow solid.  
 
1H NMR (400 MHz, d6-DMSO): δ 8.54 (d, JHH = 5 Hz, 2H), 7.34 (dd, JHH = 7 Hz, J’HH = 9 Hz, 
2H), 7.27 (d, JHH = 5 Hz, 2H), 4.54 (d, JHH = 16 Hz, 1H), 4.40 (d, JHH = 16 Hz, 1H), 3.67 (m, 
2H), 3.28 (t, JHH = 7 Hz, 1H), 2.74 (dd, JHH = 8 Hz, J’HH = 8 Hz, 1H), 2.60 (dd, JHH = 8 Hz, J’HH 
= 16 Hz); 
13C NMR (126 MHz, d6-DMSO) δ 173.32, -150.55 (ddd, JCF = 3 Hz, J’CF = 9 Hz, J’’CF = 248 
Hz), 150.25, 146.33, 139.97 (m), 137.22 (ddd, JCF =  16 Hz, J’CF = 31 Hz, J’’CF = 248 Hz), 
122.96, 112.44 (dd, JCF = 5 Hz, J’CF = 16 Hz), 53.38, 44.97, 37.86, 36.94; 
19F NMR (400 MHz, d6-DMSO + TFA): δ -137.16 (dd, JFF = 22 Hz, JFH = 9 Hz, 2H), -166.07 
(td, JFF = 22 Hz, JFH = 7 Hz); 
HRMS (m/z): [M+H]+ calcd. for C16H14N2OF3, 307.1058 ; found, 307.1060. 
 
 
2. Radioactive Chemistry 
a. Generality 




No-carrier-added [18F]fluoride was produced via the 18O(p,n)18F nuclear reaction by 
bombardment of 18O-enriched water (>95%) with 18 MeV protons using a cyclone 18/18 (IBA) 
. 18O-enriched water was purchased from Rotem or ABX. At the end of bombardment (EOB), 
the activity was transferred to the hot lab cell with helium pressure through Teflon tubing (~50 
m). 
Radioactivity was measured in a dose calibrator (Veenstrat). All the radiochemical yields are 
decay corrected. 
First experiments were realized with a low level of radioactivity (37-185 MBq (1- 5 mCi)). For 
synthesis at higher level (111 GBq (3 Ci)), an automated FASTlabTM module from GE 
Healthcare  was used.  
Thin layer chromatography (TLC) were realized silica gel Polygram® SIL G/UV254 pre-coated 
TLC sheets  eluted with MeOH (100%). The same eluent was used for all the radioactive 
analyses. The radioactive spots were quantitatively detected on a Berthold TLC scanner 
(model AR200). The TLC identity of all the labelled compounds was confirmed by UPLC after 
injection and co-injections on the same analytical system (see above) of the corresponding 
19F-fluorinated references. 
Sep-Pak cartridges (Light tC18 (360 mg, 55-105 μm) and AccellTM Plus QMA Carbonate Plus 
Light cartridges (46 mg, 37-55 μm) were obtained from Waters (Milford, USA). The tC18 SPE 
were preconditioned beforehand with MeCN (3 mL) and H2O (6 mL). 
UPLC analyses were carried out on an ACQUITY UPLC® system (Waters) equipped with a 
PDA UV  (200-400 nm) and a gamma–ray NaI detectors. The system was controlled by the 
Empower software. The ACQUITY UPLC® CSHTM C18 column (2.1 x 100 mm, 1.7 μm; 
Waters), heated at 45°C, was eluted in gradient mode with a mixture consisting of MeCN/H2O 
















0 100 0 0.5 
0.5 100 0 0.5 
6 25 75 0.5 
7 100 0 0.5 
8 100 0 0.5 
 




The semi-preparative HPLC purification was conducted on a X-Terra® RP18 HPLC column 
(10 x 250 mm, 10 μm, Waters), connected to a stand alone HPLC. The loop of a motorized 
rheodyne valve was lined to the outlet of the synthesizer module. The Waters system (600 
pump, 996 PDA UV detector (190-400  nm) was controlled by the Empower software. The 
radioactive elution profile was monitored with a custom-made Geiger-Müller (GM) radioactivity 
detector. The column was eluted with an isocratic mixture of MeCN/H2O (40/60 (v/v)) at a flow 
rate of 5 mL min-1. 
Flow reactions for difluoromethylation were performed using the Futurechem FlowStart EVO 




b. Automated  radiosynthesis of [18F]3 
The whole radiosynthesis of [18F]3 was performed on a FASTlabTM synthesizer from GE 
Healthcare. The reagents and solvents used for the radiosynthesis of [18F]3 were placed in 
small sealed vials according to a process previously reported in our laboratory[5]. Reagents 
were prepared and positioned on the FASTlabTM manifold as described and illustrated in 
Figure S2.  
 
The enriched Oxygene-18 water containing [18F]fluoride was directly recovered from the 
cyclotron target (V6) onto the FASTlab synthesizer and trapped on an ion exchange resin 
(QMA Carbonate Cartridge; from V5 to V4) and the [18O]H2O was recovered in a separate vial 
(V1) (Figure 2). The [18F]fluoride was eluted into the reactor through a central tubing (V8) with 
750 μL of a Kryptofix® (K2.2.2., 7.5 mg in 600 μL of MeCN) and K2CO3 (1.4 mg in 150 μL of H2O) 
solution. The eluent was azeotropically evaporated under vacuum and nitrogen flow by heating 
at 105°C and 120°C. Afterwards, 1 mL of 2-((bromofluoromethyl)thio)benzo[d]thiazole (1) in 
MeCN (11,1 mg; 0,04 mmol; 1.1 mL) was then transferred to the dry potassium 
[18F]fluoride/K2.2.2. complex through the central tubing of the reactor (V8) and heated to 120 °C 
for 5 min (labeling). After labeling, the reaction medium containing the 2-
((di[18F]fluoromethyl)thio)benzo[d]thiazole ([18F]2) was diluted three times in syringe S2 (V11) 
with H2O (~12 mL) (V15), and the labeled compound [18F]2 was trapped on a tC18 cartridge 
(from V17 to V18). The reactor was washed with H2O (~4 mL), and this solution was passed 
through the cartridge. An solution containing NaIO4 (51,3 mg; 0,24 mmol) and RuCl3·xH2O 
(1,7 mg; 0,008 mmol) in H2O (4 mL) (V14) was passed through the tC18 cartridge and the 
oxidation of [18F]2 was performed on it for 5 min at room temperature. Thereafter, the crude 
labeled compound [18F]3 was eluted from the tC18 cartridge (from V18 to V17; reverse flow 
elution) with MeCN (2 mL; syringe S3, V24) and recovered into the reactor via its central 
tubing. After dilution with H2O (4 mL) the resulting solution was transferred with syringe S2 
(V11) into the semi-preparative HPLC loop (V9; 6 mL) through a Sterifix® Paed filter (0.2 μm). 
The reactor was then washed with water (~2 mL), and the aqueous solution was transferred 
into the HPLC loop. The semi-preparative HPLC purification was performed using MeCN/H2O 
(isocratic, 40/60 (v/v) at 5 mLmin-1). The HPLC peak corresponding to [18F]3 was collected 
(retention time = 16.5-19.5 min) in a sealed vial containing water (~30 mL). Afterwards, [18F]3 
was pumped (from V10), 6 mL by 6 mL, with the syringe S2 (V11) and further passed through 
a preconditioned tC18 cartridge (from V21 to V22). Finally, [18F]3 was eluted into the outlet 
vial (V20) with reverse flow of DMSO (1 mL, syringe S3 (V24)).  
 















c. Optimization of the labeling and oxidative steps 
The conditions screened for the labeling and oxidative steps are summarized in the following 
table (Table S2) and each radiochemical experiment was conducted three times (n=3).   
The Radio-LC and a LC of the references are also shown after the first table to confirm the 
formation of the desired product (Figures S3-6). 
 





















STEP I STEP II
 
 
Table S2 :  Optimization of the reaction conditions for the preparation of [18F]3 
Entry Reaction Deviation from 
usual conditions1,2 
RCY(%) 
1 I none 15.2 ± 0.3 
2 I 85°C  12.7 ± 0.2 
3 I 85°C, DCE 7,2 ± 0,5 
4 I 85°C, DMSO 0 
5 I Precursor 1 (80 
µmol) 
5.9 ± 2.4 
6 I Et4N+HCO3- 12.8 ± 1.1 
7 II none 13.4 ± 0.4 
8 II NaIO4 (0.12 mmol) 9.6 ± 0.9 
1 Usual conditions for I : 1 (40 µmol),  K222 (10 µmol), K2CO3 (20 µmol), MeCN, 120°C, 5min 




Figure S3 : UPLC radio-chromatogram of [18F]2. 





Figure S4 : UPLC UV-chromatogram (254 nm) of an authentic reference 2. 
 
 
Figure S5 : UPLC radio-chromatogram of [18F]3 
 





Figure S6 : UPLC UV-chromatogram (239 nm) of an authentic reference 3 
 
For each experiment, the RCY (decay-corrected) of [18F]2 and [18F]3 was determined after 
SPE purification on an aliquot of the final solution according to the following formula taking 
into account the TLC and HPLC radiochemical purity of the isolated product. 
 
𝑅𝐶𝑌 (%, 𝑑𝑐) =  
𝑟𝑎𝑑𝑖𝑜𝑇𝐿𝐶 𝑝𝑢𝑟𝑖𝑡𝑦 (%) × 𝑟𝑎𝑑𝑖𝑜𝑈𝑃𝐿𝐶 𝑝𝑢𝑟𝑖𝑡𝑦 (%) × 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑜𝑓 𝑐𝑟𝑢𝑑𝑒 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 (𝑑𝑐)
𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝑑𝑐) 




d. Isolation and determination of molar activity of the sulfone [18F]3 
The fully automated synthesis of the 18F-labeled sulfone was realized with the FastLab module 
as described in section 2b using the best conditions reported in section 2c (Table 2, entry 7). 
The molar activity of [18F]3 was determined on a aliquot of the DMSO solution (5 µL). After 
UPLC elution, the radioactive peak associated to the non-radioactive sulfone was collected 
and counted and the UV area of the peak determined (  = 239 nm). The decay-corrected 
activity was calculated and the corresponding amount of 3 was determined using the 
calibration curve previously obtained with the non-radioactive reference (Figure S7). A molar 
activity between 74 and 185 GBq/µmol (2 and 5 Ci/µmol) was calculated.  
These analyses were performed with the UPLC system and the conditions reported above. 





Figure S7 : Calibration curve of 3 
 
For the following photoredox reaction, aliquots of the recovered DMSO solution of [18F]3 were 
used.  
 




    
[18F]5
 
A solution of acyclovir (4.5mg, 20 µmol), [Ir(ppy)3] (0.01 µmol) in DMSO (200 µL) was 
prepared. Then  [18F]3 in DMSO (around 37 MBq/ 1mCi) was added and the solution was 
injected through a 100 µL microchip, pumped with DMSO at a flow rate of 50 µL/min (residence 
time of 2 min) and irradiated under blue LED (470nm, 2W), at a temperature of 35°C (see the 
instrument in Figure S8). The exited solution was analysed by Radio-TLC and Radio-UPLC 
for radiochemical yield determination. 

















Calibration curve for molar activity determination





Figure S8 : Flow chemistry instrument used for 18F-difluoromethylation; Futurechemistry 
Radiochemical yields were determined according the following formula and are not decay 
corrected. 
𝑅𝐶𝑌 (%) =
𝐿𝐶 𝑝𝑢𝑟𝑖𝑡𝑦(%) ∗ 𝑇𝐿𝐶 𝑝𝑢𝑟𝑖𝑡𝑦(%)
100
 
For instance :  
 
Figure S9: Radio TLC of [18F]5 
Table S3 : Results Radio-TLC [18F]5 
Rf Ratio 




0.03 26 (impurity/byproduct) 
0.79 74 (product) 
 
Figure S10 : UPLC radio-chromatogram of [18F]5 
 
Figure S11 : UPLC UV-chromatogram of an authentic reference 5 
𝑅𝐶𝑌 (%) =







𝑅𝐶𝑌 (%) = 74% (𝑛𝑑𝑐) 
 
NB : In some cases, some peaks at 0.6 and 0.9 min can be observed on the radio-UPLC 
chromatograms. Those two peaks were collected and analysed by radio-TLC. Their Rf being 




of 0, they were not taking into account for the determination of the LC purity (as they were 
already taken into account in the determination of the TLC purity). 
The results of the different optimization tests are summarized in the following table : 
Conditions : Acyclovir (20 µmol) , [Ir(ppy)3] (0.01 µmol), [18F]3 (37 MBq), DMSO (200 µL), 
2min, 35°C, blue LED (2 W) 
 
Table S4 : Screening of experimental conditions for the 18F-difluoromethylation reaction 
Entry Deviation from usual 
conditions 
RCY(%, ndc) 
1 none 70 ± 7 
2 55°C 51 ± 10 
3 DMF 44 ± 1 
4 30s 60 ± 8 
5 Ir(ppy)3 (0.001 µmol) 42 
6 Benzophenone1 47 ± 5 
7 Ru(bpy)3 0 
8 H2O (50 µL) 45 ± 10 
9 After HPLC purification 42 ± 42 
1 benzophenone (10 µmol), 365nm, 2 Isolated Radiochemical Yield (n=4) 
Only a few solvents allows a complete solubilization of the substrate, DMSO gives better 
results than DMF. 
The temperature is also an important parameter:  too high temperature leads to more 
degradation. 
The best conditions for the 18F-difluoromethylation are 35°C, [Ir(ppy)3] (0.01 µmol), 2 minutes 
of residence time and DMSO as solvent  (see entry 1, Table S4). These conditions were 





















f. Isolation and Molar activity of CHF18FAcyclovir [18F]5 
After completion of the photoredox reaction that was realized as described in the previous 
section, H2O (5 mL) was added. The purification of [18F]5 was then conducted at 5 mL/min on 
the semi preparative HPLC column described above. The eluent was a mixture of H2O (95%) 
and MeCN (5%). Based on the amount of sulfone used for the photochemistry reaction, the 
RCY of [18F]5 purified by HPLC was of  42 ± 4 % (dc). 
Then following the same process as for compound 3, a calibration curve (Figure S12) was 
realized with 5 to determine the molar activity of the product. 
 
Figure S12 : Calibration curve of 5 




















Calibration curve of 5, µmol=f(area)








g. Mechanistic studies 
The proposed mechanism of the reaction is represented in the following figure: (Figure S13) 
 
Figure S13 : Proposed mechanism 
 
No product was obtained in the absence of light or photocatalyst (entries 1 and 2, Table S5) 
and in presence of TEMPO (entry 3), suggesting that radical species are involved, as 
proposed in the mechanism. 
Table S5 : Tests for mechanistic studies 
Entry Deviation from usual 
conditions 
RCY (%) 
1 No catalyst 0 
2 No light 0 
3 TEMPO 0 
 
 
h. General procedure for 18F-difluoromethylation 




A solution of the substrate (20 µmol), [Ir(ppy)3] (0.01 µmol) in DMSO (200 µL) was prepared. 
Then the [18F]3 in DMSO (around 37 MBq/1 mCi) was added. The solution was injected in a 
100 µL microchip, pumped with DMSO at a flow rate of 50 µL/min (residence time of 2 min) 
and irradiated under blue LED (470 nm, 2 W), at a temperature of 35°C . 






General procedure  using indole (2.3 mg, 20 µmol) yielded to 18 ± 1% as RCY (ndc, on crude 
product) of the title compound (see Table S6 and Figures S14 and S15 for radio LC of the 
labelled compound and LC analysis of the reference). 
 
Table S6 : Radiochemical yield of [18F]6 






1 60  32  19  
2 59  30  18  
3 61  30  18  
Radiochemical Yield + Deviation (%) 18 ± 1  
 
Figure S14 : UPLC radio-chromatogram of [18F]6 





Figure S15 : UPLC UV-chromatogram of an authentic reference 6 
 
2-(difluoromethyl)-1H-benzimidazole [18F]7a; 4-(difluoromethyl)-1H-benzimidazole 
[18F]7b ;  
5-(difluoromethyl)-1H-benzimidazole [18F]7c 
[18F]7a       [
18F]7b    [
18F]7c  
General procedure using benzimidazole (2.4 mg, 20 µmol) yielded respectively to 20 ± 1%, 41 
± 5 % and 10 ± 4 %  as RCYs (ndc, on crude product) of the title compounds [18F]7a, [18F]7b 
and [18F]7c (see Table S7 and Figures S16 to S18 for radio LC of the labelled compound and 
LC analysis of the references). 
 
Table S7 : Radiochemical yield of [18F]7 
Reaction Radio-TLC 
purity (%) 
Radio-LC purity  
(%) 
Radiochemical Yield  
(%) 
 a+b+c a b c a b c 
1 72 27 65 8 19 47 6 
2 64 32 55 13 21 36 8 
3 70 27 53 20 19 37 14 
Radiochemical Yield + Deviation (%) 20 ± 1 41 ± 5 10 ± 4 
 
 





Figure S16 : UPLC radio-chromatogram of [18F]7 
 
Figure S17 : UPLC UV-chromatogram of an authentic reference 7a 
 





Figure S18 : UPLC UV-chromatogram of an authentic reference 7b 
 






General procedure using 4-methyl-1H-pyrrolo[2,3-b]pyridine (2.6 mg, 20 µmol) yielded 
respectively to 61 ± 1% and 7%  as RCYs (ndc, on crude product) of the title compounds 




[18F]8a  and [18F]8b (see Table S8 and Figures S20 to S22 for radio LC of the labelled 
compound and LC analysis of the references). 
Table S8 : Radiochemical yield of [18F]8 







 a+b a b a b 
1 65 90 10 59 7 
2 69 90 10 62 7 
3 68 90 10 61 7 
Radiochemical Yield + Deviation (%) 61 ± 1 7 
 
 
Figure S20 : UPLC radio-chromatogram of [18F]8 
 




Figure S21 : UPLC UV-chromatogram of an authentic reference 8a 
 






General procedure using 6-methyl-1H-pyrazolo[3,4-b]pyridine (2.2 mg, 20 µmol) yielded 
respectively to 20 ± 1% and  54 ± 2%  as RCYs (ndc, on crude product) of the title compounds 
[18F]9a  and [18F]9b (see Table S9 and Figures S23 to S25 for radio LC of the labelled 
compound and LC analysis of the references). 
 
Table S9 : Radiochemical yield of [18F]9 







 a + b a b a b 
1 74 25 75 19 56 
2 73 29 71 21 52 
3 75 28 72 20 54 
Radiochemical Yield + Deviation (%) 20 ± 1 54 ± 2 
 





Figure S23 : UPLC radio-chromatogram of [18F]9 
 
 
Figure S24 : UPLC UV-chromatogram of an authentic reference 9a 
 










General procedure using 2-(3,5-dichloro-4-pyridyl)-N,N-dimethyl-acetamide (4.7 mg, 20 µmol) 
yielded to 57 ± 5% as RCY (ndc, on crude product) of the title compound (see Table S10 and 
Figures S26 and S27 for radio LC of the labelled compound and LC analysis of the reference). 
 
Table S10 : Radiochemical yield of [18F]10 







1 75 82 62 
2 71 73 52 
3 65 93 60 
Radiochemical Yield + Deviation (%) 57 ± 5 
 
 





Figure S26 : UPLC radio-chromatogram of [18F]10 
 




General procedure using 3-chloro-6,7-dihydro-5H-cyclopenta[c]pyridine-4-carbonitrile (3.6 
mg, 20 µmol) yielded to 45 ± 2% as RCY (ndc, on crude product) of the title compound (see 




Table S11 and Figures S28 and S29 for radio LC of the labelled compound and LC analysis 
of the reference). 
 
Table S11 : Radiochemical yield of [18F]11 







1 50 95 47 
2 43 100 43 
3 46 100 46 
Radiochemical Yield + Deviation (%) 45 ± 2 
 
 
Figure S28 : UPLC radio-chromatogram of [18F]11 
 










General procedure using 2-chloro-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile (3.6 
mg, 20 µmol) yielded to 42 ± 13% as RCY (ndc, on crude product) of the title compound (see 
Table S12 and Figures S30 and S31 for radio LC of the labelled compound and LC analysis 
of the reference). 
 
Table S12 : Radiochemical yield of [18F]12 







1 45 100 45 
2 47 62 29 
3 63 87 55 
Radiochemical Yield + Deviation (%) 42 ± 13 
 





Figure S30 : UPLC radio-chromatogram of [18F]12 
 
 









General procedure using 2-tetrahydropyran-4-ylpyrimidin-5-amine (3.6 mg, 20 µmol) yielded 
to 69 ± 3%  as RCY (ndc, on crude product) of the title compound (see Table S13 and Figures 
S32 and S33 for radio LC of the labelled compound and LC analysis of the reference). 
 
Table S13 : Radiochemical yield of [18F]13 
Reaction Radio-TLC purity  
(%) 




1 71 100 71 
2 67 98 66 
3 72 99 71 
Radiochemical Yield + Deviation (%) 69 ± 3 
 
 
Figure S32 : UPLC radio-chromatogram of [18F]13 
 
Figure S33 : UPLC UV-chromatogram of an authentic reference 13 








General procedure using 4-chloro-6-methoxy-pyrimidin-5-amine (3.2 mg, 20 µmol) yielded to 
57 ± 6 %  as RCY (ndc, on crude product) of the title compound (see Table S14 and Figures 
S34 and S35 for radio LC of the labelled compound and LC analysis of the reference). 
 
Table S14 : Radiochemical yield of [18F]14 
Reaction Radio-TLC purity  
(%) 




1 57 90 51 
2 69 90 62 
3 76 85 64 
Radiochemical Yield + Deviation (%) 57 ± 6 
 
 
Figure S34 : UPLC radio-chromatogram of [18F]14 











General procedure using 5-methylpyrimidin-2-amine (2.2 mg, 20 µmol) yielded to 43 ± 3% as 
RCY (ndc, on crude product) of the title compound (see Table S15 and Figures S36 and S37 
for radio LC of the labelled compound and LC analysis of the reference). 
 
Table S15 : Radiochemical yield of [18F]15 







1 41 100 41 
2 42 100 42 
3 46 100 46 
Radiochemical Yield + Deviation (%) 43 ± 3 
 





Figure S36 : UPLC radio-chromatogram of [18F]15 
 
 










General procedure using 2-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one (3.3 mg, 20 
µmol), with a residence time of 4 min and [Ir(ppy)3] (0.05 µmol) yielded to 32 ± 4% as RCY 
(ndc, on crude product) of the title compound (see Table S16 and Figures S38 and S39 for 
radio LC of the labelled compound and LC analysis of the reference). 
 
Table S16 : Radiochemical yield of [18F]16 







1 53 66 36 
2 59 46 27 
3 55 60 33 
Radiochemical Yield + Deviation (%) 32 ± 4 
 
 
Figure S38 : UPLC radio-chromatogram of [18F]16 










General procedure using 1H-pyrimido[4,5-d]pyridazine-2,4-dione (3.3 mg, 20 µmol) with a 
residence time of 4 min and [Ir(ppy)3] (0.05 µmol) yielded to 75 ± 1%  as RCY (ndc, on crude 
product) of the title compound (see Table S17 and Figures S40 and S41 for radio LC of the 
labelled compound and LC analysis of the reference). 
Table S17 : Radiochemical yield of [18F]17 







1 79 96 76 
2 76 96 74 
3 77 96 74 
Radiochemical Yield + Deviation (%) 75 ± 1 
 





Figure S40 : UPLC radio-chromatogram of [18F]17 
 
 










General procedure using methyl 2-(3,5-dichloro-1-tetrahydropyran-2-yl-pyrazolo[3,4-
b]pyridin-4-yl)acetate  (6.9 mg, 20 µmol), with a residence time of 4 min and [Ir(ppy)3] (0.05 
µmol) yielded to 38 ± 5% as RCY (ndc, on crude product) of the title compound (see Table 
S18 and Figures S42 and S43 for radio LC of the labelled compound and LC analysis of the 
reference). 
 
Table S18 : Radiochemical yield of [18F]18 







1 74 60 44 
2 76 43 33 
3 69 58 40 
Radiochemical Yield + Deviation (%) 38 ± 5 
 
 
Figure S42 : UPLC radio-chromatogram of [18F]18 
 












General procedure using 6-methyl-2-methylsulfanyl-8H-pyrimido[4,5-d]pyrimidine-5,7-dione 
(4.5 mg, 20 µmol) yielded to 43 ± 3 % as RCY (ndc, on crude product) of the title compound 
(see Table S19 and Figures S44 and S45 for radio LC of the labelled compound and LC 
analysis of the reference). 
 
Table S19 : Radiochemical yield of [18F]19 







1 76 60 46 
2 70 60 42 
3 67 60 40 
Radiochemical Yield + Deviation (%) 43 ± 3 
 





Figure S44 : UPLC radio-chromatogram of [18F]19 
 
Figure S45 : UPLC UV-chromatogram of an authentic reference 19 
 
8-(difluoromethyl)-1,3,7-trimethyl-purine-2,6-dione/ CHF18F-caffeine [18F]20 
[18F]20  
General procedure using caffeine (3.9 mg, 20 µmol) yielded to 51 +/- 1% as RCY (ndc, on 
crude product) of the title compound (see Table S20 and Figures S46 and S47 for radio LC of 
the labelled compound and LC analysis of the reference). 






Table S20 : Radiochemical yield of [18F]20 







1 50 100 50 
2 50 100 50 
3 52 100 52 
Radiochemical Yield + Deviation (%) 51 ± 1 
 
 
Figure S46 : UPLC radio-chromatogram of [18F]20 
 
Figure S47 : UPLC UV-chromatogram of an authentic reference 20 





8-(difluoromethyl)-1,3-dimethyl-7H-purine-2,6-dione / CHF18F-theophylline [18F]21 
[18F]21
 
General procedure using theophylline (3.6 mg, 20 µmol) yielded to 42 ± 6% as RCY (ndc, on 
crude product) of the title compound (see Table S21 and Figures S48 and S49 for radio LC of 
the labelled compound and LC analysis of the reference). 
 
Table S21 : Radiochemical yield of [18F]21 







1 51 96 48 
2 43 83 36 
3 57 74 42 
Radiochemical Yield + Deviation (%) 42 ± 6 
 
 
Figure S48 : UPLC radio-chromatogram of [18F]21 
 





Figure S49 : UPLC UV-chromatogram of an authentic reference 21 
 
 





General procedure using pentoxyfilline (5.6 mg, 20 µmol) yielded to  30 ± 5  %  as RCY (ndc, 
on crude product) of the title compound (see Table S22 and Figures S50 and S51 for radio 
LC of the labelled compound and LC analysis of the reference). 
 
Table S22 : Radiochemical yield of [18F]22 
Reaction Radio-TLC purity  
(%) 




1 34 100 34 
2 43 70 31 
3 30 85 25 
Radiochemical Yield + Deviation (%) 30 ± 5  
 





Figure S50: UPLC radio-chromatogram of [18F]22 
  
Figure S51 : UPLC UV-chromatogram of an authentic reference 22 
5-(difluoromethyl)-1,3-dimethyl-pyrimidine-2,4-dione / CHF18F-dimethyl-uracil [18F]23 
[18F]23
 
General procedure using dimethyl-uracil (2.8 mg, 20 µmol) yielded to 54 ± 1%  as RCY (ndc, 
on crude product) of the title compound (see Table S23 and Figures S52 and S53 for radio 
LC of the labelled compound and LC analysis of the reference). 





Table S23 : Radiochemical yield of [18F]23 







1 78 70 55 
2 70 75 53 
3 75 70 53 
Radiochemical Yield + Deviation (%) 54 ± 1 
 
 
Figure S52 : UPLC radio-chromatogram of [18F]23 
 
Figure S53 : UPLC UV-chromatogram of an authentic reference 23 






6-amino-5-(difluoromethyl)-1H-pyrimidin-2-one [18F]24a and 6-amino-4-
(difluoromethyl)-1H-pyrimidin-2-one [18F]24b/ CHF18F -cytosine [18F]24 
[18F]24a [18F]24b  
General procedure using cytosine (3.2 mg, 20 µmol) yielded to 60 ± 2 % as RCY (ndc, on 
crude product) of the title compounds. The two isomers were not distincted in UPLC analyses, 
the ratio was then not determined. (see Table S24 and Figures S54 and S55 for radio LC of 
the labelled compound and LC analysis of the reference). 
 
Table S24 : Radiochemical yield of [18F]24 







1 58 100 58 
2 57 100 57 
3 62 100 62 
Radiochemical Yield + Deviation (%) 60 ± 2  
 
 
Figure S54 : UPLC radio-chromatogram of [18F]24 
 





Figure S55 : UPLC UV-chromatogram of an authentic reference 24a and 24b 
8-(difluoromethyl)-9H-purin-6-amine  / CHF18F-adenine [18F]25 
[18F]25   
General procedure using adenine (2.7 mg, 20 µmol) yielded to  65 ± 6 % as RCY (ndc, on 
crude product) of the title compound (see Table S25 and Figures S56 and S57 for radio LC of 
the labelled compound and LC analysis of the reference). 
 
Table S25 : Radiochemical yield of [18F]25 







1 76 94 71 
2 65 100 65 
3 59 100 59 
Radiochemical Yield + Deviation (%) 65 ± 6  
 





Figure S56 : UPLC radio-chromatogram of [18F]25 
 
Figure S57 : UPLC UV-chromatogram of an authentic reference 25 
 
(1S)-5-(difluoromethyl)-1-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-
2-yl]pyrimidine-2,4-dione / CHF18F-uridine [18F]26 






General procedure using  uridine (4.8 mg, 20 µmol) yielded to  71 ± 4 %  as RCY (ndc, on 
crude product) of the title compound (see Table S26 and Figures S58 and S59 for radio LC of 
the labelled compound and LC analysis of the reference). 
 
Table S26 : Radiochemical yield of [18F]26 
Reaction Radio-TLC purity  
(%) 




1 75 100 75 
2 76 100 76 
3 67 100 67 
Radiochemical Yield + Deviation (%) 71 ± 4  
Figure S58 : UPLC radio-chromatogram of [18F]26 





Figure S59 : UPLC UV-chromatogram of an authentic reference 26 
 
(1S)-4-amino-5-(difluoromethyl)-1-[(3R,4S,5R)-3,4-dihydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one / CHF18F-cytidine [18F]27 
[18F]27
 
General procedure using cytidine (4.8 mg, 20 µmol) yielded to  65 ± 2 %  as RCY (ndc, on 
crude product) of the title compound (see Table S27 and Figures S60 and S61 for radio LC of 
the labelled compound and LC analysis of the reference). 
 
Table S27 : Radiochemical yield of [18F]27 
Reaction Radio-TLC purity  
(%) 




1 64 100 64 
2 67 100 67 
3 66 100 66 
Radiochemical Yield + Deviation (%) 65 ± 2 
 





Figure S60 : UPLC radio-chromatogram of [18F]27 
 
 
Figure S61 : UPLC UV-chromatogram of an authentic reference 27 
(3R,4S,5R)-2-[(9S)-6-amino-8-(difluoromethyl)purin-9-yl]-5-(hydroxymethyl) 
tetrahydrofuran-3,4-diol  / CHF18F-Adenosine [18F]28 






General procedure using adenosine (5.3 mg, 20 µmol) yielded to  59 ± 5% as RCY (ndc, on 
crude product) of the title compound (see Table S28 and Figures S62 and S63 for radio LC of 
the labelled compound and LC analysis of the reference). 
 
Table S28 : Radiochemical yield of [18F]28 







1 64 97 62 
2 59 100 59 
3 55 100 55 
Radiochemical Yield + Deviation (%) 58 ± 4 
 
 
Figure S62 : UPLC radio-chromatogram of [18F]28 





Figure S63 : UPLC UV-chromatogram of an authentic reference 28 
 (9S)-2-amino-8-(difluoromethyl)-9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) 
tetrahydrofuran-2-yl]-1H-purin-6-one / CHF18F-guanosine [18F]29 
[18F]29
 
General procedure using guanosine (5.7 mg, 20 µmol) yielded to  62 ± 6% as RCY (ndc, on 
crude product) of the title compound (see Table S29 and Figures S64 and S65 for radio LC of 
the labelled compound and LC analysis of the reference). 
 
Table S29 : Radiochemical yield of [18F]29 







1 61 100 61 
2 68 100 68 
3 56 100 56 
Radiochemical Yield + Deviation (%) 62 ± 6  
 





Figure S64 : UPLC radio-chromatogram of [18F]29 
 
Figure S65 : UPLC UV-chromatogram of an authentic reference 29 
 
4-chloro-2-(difluoromethyl)-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-pyrimidin-5-
amine / CHF18F-moxonidine analogue [18F]30 
[18F]30  




General procedure using moxonidine analogue (4.5 mg, 20 µmol) yielded to 65 ± % 4 as RCY 
(ndc, on crude product) of the title compound (see Table S30 and Figures S66 and S67 for 
radio LC of the labelled compound and LC analysis of the reference). 
 
Table S30 : Radiochemical yield of [18F]30 
Reaction Radio-TLC purity  
(%) 




1 63 100 63 
2 69 100 69 
3 61 100 61 
Radiochemical Yield + Deviation (%) 65 ± 4 
 
 
Figure S66 : UPLC radio-chromatogram of [18F]30 
 













General procedure using compound 39 (6.1 mg, 20 µmol) yielded respectively to 14.8%, 3.8% 
and 7.1% as RCYs (ndc, on crude product) of [18F]31a, [18F]31b  and [18F]31c (see Table S31 
and Figures S68 to S71 for radio LC of the labelled compound and LC analysis of the 
reference). 
 
Table S31 : Radiochemical yield of [18F]31 
Reaction Radio-TLC 
purity (%) 
Radio-LC purity  
(%) 
Radiochemical Yield  
(%) 
 a+b+c a b c a b c 
1 80 20 5 10 16 4 8 
2 75 18 6 9 13.5 4.5 7 
3 78 19 4 8 14.8 3.1 6.2 
Radiochemical Yield + Deviation (%) 14.8 ± 
0.3 
3.8 ± 0.7  7.1 ± 
0.9  
 




Different analyses conditions were used, to ensure a better separation of the different 
isomers. 
The new analytic gradient is disclosed in the table below : (Table S32) 











0 100 0 0.5 
0.5 
 
100 0 0.5 
0.6 70 30 0.5 
10 65 35 0.5 
10.1 0 100 0.5 
11 0 100 0.5 
12 100 0 0.5 
13 100 0 0.5 
 
 
Figure S68 : UPLC radio-chromatogram of [18F]31 





Figure S69 : UPLC UV-chromatogram of an authentic reference 31a 
 
 
Figure S70 : UPLC UV-chromatogram of an authentic reference 31b 
 





Figure S71 : UPLC UV-chromatogram of an authentic reference 31c 
 
Then a Semi-Prep HPLC, using a mixture of MeCN/H2O (1/1) as eluent was performed to 
recover [18F]31a and [18F]31b with respective isolated RCYs dc of 4.2 ± 0.3 % and 1.5 ± 0.1 
% (n=3). Starting from 7 mCi, 0.1 mCi of [18F]31b was isolated after 20 minutes (photoredox 




3. Comparison batch fluorine-19/flow fluorine-18 conditions 
Some of the substrates were also tested in non-radioactive chemistry to able a comparison 
between non-radioactive and radioactive chemistry and put in evidence the difference of 
reactivity between both conditions. The general procedure and the results are reported just 
below. 
a. General procedure for batch fluorine-19 conditions 
 
A solution of the substrate (0.10 mmol), 2-((Difluoromethyl)sulfonyl)benzo[d]thiazole 3 (37 mg, 
0.15 mmol, 1.5 equiv.), and [Ir(ppy)3] (3.3 mg, 0.005 mmol, 5 mol%) in DMSO (0.5 mL) was 
prepared. The vial was put over a LED (455nm, 1 W, 55°C, see equipment below, Figure S72) 
and stirred for 24 hours. 




2-((Difluoromethyl)sulfonyl)benzo[d]thiazole 3 (37 mg, 0.15 mmol, 1.5 equiv.), and [Ir(ppy)3] 
(3.3 mg, 0.005 mmol, 5 mol%) were added again to the reaction, and the crude mixture was 
irradiated for another 24 hours. 
Yields were determined by 19F NMR after 24 and 48h reaction time. 
 
 
Figure S72 : 1W LED (455nm) equipment used for non-radioactive batch conditions 
 
b. Results 
The general procedure was applied to 10 compounds of the scope and the results are 
presented in the following table (Table S33) : 
 
Table S33 :  Comparative table for 19F vs 18F conditions 



























  30 30 15 71 ± 5 







  13 
a/b : 3/1 
12 
a/b : 2/1 
NA 67 ± 2 









a/b : 1/2 
6.5 
a/b: 2/1 
74 ± 2 
a/b : 30/70 
12  
  10 15 NA 43 ± 10 
14  
  20 25 NA 57 ± 7 
15  
  32 30 26 43 ± 3 
20  
  34 45 4 50 ± 1 
23  
  13 13 5 54 ± 1 
28  
  10 10 NA 59 ±5 

















a/b/c : 16/1/1 
25 ± 3 
a/b/c : 4/1/2 
 
It is interesting to note that in most cases, yields are way lower in non-radioactive chemistry 
(molecules 5, 8, 9, 12, 14, 23, 28) while similar results are obtained with both fluorine-19 
conditions.  
Noteworthy, adding new portion of the difluoromethylating agent (3), and catalyst doesn’t lead 
to much yield improvement suggesting the formation of a poisoning reagent preventing the 
reaction to continue. 
 
Finally, the isomers ratio can be slightly different between all conditions. 
All these results clearly showed an improved reactivity of the reaction using fluorine-18. 
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a. 1H, 13C and 19F NMR of 1 






















b. 1H, 13C and 19F NMR of 2 























c. 1H, 13C and 19F NMR of 3 





















d. 1H, 13C and 19F NMR of 5 
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e. 1H, cosy, NOE, 13C and 19F NMR of 6 
































f. 1H, 13C and 19F NMR of 7a 






















g. 1H, 13C and 19F NMR of 7b 





















h. 1H, 13C and 19F NMR of 7c 
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i. 1H, cosy, 13C and 19F NMR of 8a 



























j. 1H, cosy,13C and 19F NMR of 8b 


























k. 1H, 13C and 19F NMR of 9a
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l. 1H, 13C and 19F NMR of 9b 






















m. 1H, 13C and 19F NMR of 10 




















n. 1H, 13C and 19F NMR of 11 





















o. 1H, 13C and 19F NMR of 12 





















p. 1H, 13C and 19F NMR of 13 

























q. 1H, 13C and 19F NMR of 14 





















r. 1H, 13C and 19F NMR of 15 





















s. 1H, 13C and 19F NMR of 16 





















t. 1H, 13C and 19F NMR of 17 






















u. 1H, 13C and 19F NMR of 18 




















v. 1H, 13C and 19F NMR of 19 
 
19














w. 1H, 13C and 19F NMR of 20 
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x. 1H, 13C and 19F NMR of 21 



























y. 1H, 13C and 19F NMR of 22 






















z. 1H, 13C and 19F NMR of 23 



























aa. 1H, HSQC, HMBC and 19F NMR of 24a 
 


















SUPPORTING INFORMATION          
 
S-195 
   
24a




bb. 1H, 13C and 19F NMR of 24b 






















cc. 1H, 13C and 19F NMR of 25 





















dd. 1H, 13C and 19F NMR of 26 





















ee. 1H, HSQC/HMBC and 19F NMR of 27 


























ff. 1H, 13C and 19F NMR of 28 





















gg. 1H, 13C and 19F NMR of 29 





















hh. 1H, 13C and 19F NMR of 30 




















ii. 1H, 13C and 19F NMR of 31a 




















jj. 1H, HSCQ, HMBC and 19F NMR of 31b 
31b




























































































kk. 1H, HSCQ, HMBC and 19F NMR of 31c 
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ll. 1H and 13C NMR of 35
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mm. 1H and 13C NMR of 36 
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nn. 1H, 13C and 19F NMR of 39
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